Catalyst Pharmaceuticals, Inc. (CPRX)
NASDAQ$20.87-0.33 (-1.56%)
Market Cap
$2.57B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
534 of 925
Rank in Industry
309 of 528
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
CPRX Insider Trading Activity
CPRX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $36,521,689 | 25 | 100 |
Related Transactions
| Daly Richard J | President and CEO | 0 | $0 | 1 | $276,735 | $-276,735 |
| Harper Molly | director | 0 | $0 | 2 | $471,949 | $-471,949 |
| Tierney David S | director | 0 | $0 | 2 | $693,455 | $-693,455 |
| Del Carmen Jeffrey | Chief Commercial Officer | 0 | $0 | 3 | $1.48M | $-1.48M |
| Elsbernd Brian | Chief Compliance/Legal Officer | 0 | $0 | 3 | $2.14M | $-2.14M |
| Miller Steve | Chief Op. & Scientific Officer | 0 | $0 | 2 | $4.15M | $-4.15M |
| INGENITO GARY | Chief Med. & Reg. Officer | 0 | $0 | 6 | $9.07M | $-9.07M |
| MCENANY PATRICK J | Chairman of Board of Directors | 0 | $0 | 6 | $18.23M | $-18.23M |
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular …
Insider Activity of Catalyst Pharmaceuticals, Inc.
Over the last 12 months, insiders at Catalyst Pharmaceuticals, Inc. have bought $0 and sold $36.52M worth of Catalyst Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Catalyst Pharmaceuticals, Inc. have bought $130,960 and sold $17.44M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 30,000 shares for transaction amount of $89,100 was made by MCENANY PATRICK J (President and CEO) on 2020‑09‑30.
List of Insider Buy and Sell Transactions, Catalyst Pharmaceuticals, Inc.
| 2025-03-06 | Sale | INGENITO GARY | Chief Med. & Reg. Officer | 180,096 0.1485% | $21.67 | $3.9M | -2.72% | |
| 2025-03-05 | Sale | INGENITO GARY | Chief Med. & Reg. Officer | 44,904 0.0371% | $22.09 | $991,929 | -3.20% | |
| 2025-03-03 | Sale | Elsbernd Brian | Chief Compliance/Legal Officer | 62,975 0.053% | $22.98 | $1.45M | -2.91% | |
| 2025-03-03 | Sale | Del Carmen Jeffrey | Chief Commercial Officer | 30,423 0.0255% | $22.89 | $696,382 | -2.91% | |
| 2024-12-10 | Sale | Miller Steve | Chief Op. & Scientific Officer | 50,000 0.0417% | $21.93 | $1.1M | -0.05% | |
| 2024-11-27 | Sale | INGENITO GARY | Chief Med. & Reg. Officer | 12,000 0.0102% | $22.72 | $272,654 | -1.21% | |
| 2024-11-27 | Sale | Harper Molly | director | 17,500 0.0144% | $22.00 | $385,000 | -1.21% | |
| 2024-11-26 | Sale | Elsbernd Brian | Chief Compliance/Legal Officer | 13,256 0.011% | $21.63 | $286,704 | +0.64% | |
| 2024-11-20 | Sale | MCENANY PATRICK J | Chairman of Board of Directors | 72,500 0.0612% | $21.29 | $1.54M | +4.00% | |
| 2024-11-20 | Sale | INGENITO GARY | Chief Med. & Reg. Officer | 38,000 0.032% | $21.20 | $805,562 | +4.00% | |
| 2024-11-19 | Sale | MCENANY PATRICK J | Chairman of Board of Directors | 98,345 0.0823% | $21.19 | $2.08M | +2.71% | |
| 2024-11-14 | Sale | MCENANY PATRICK J | Chairman of Board of Directors | 44,655 0.0376% | $21.75 | $971,336 | +1.27% | |
| 2024-11-13 | Sale | MCENANY PATRICK J | Chairman of Board of Directors | 92,500 0.0776% | $22.98 | $2.13M | -3.68% | |
| 2024-11-12 | Sale | MCENANY PATRICK J | Chairman of Board of Directors | 262,000 0.221% | $23.26 | $6.09M | -4.67% | |
| 2024-11-11 | Sale | MCENANY PATRICK J | Chairman of Board of Directors | 230,000 0.1936% | $23.55 | $5.42M | -6.31% | |
| 2024-08-21 | Sale | Tierney David S | director | 15,000 0.0124% | $20.10 | $301,455 | +5.03% | |
| 2024-08-20 | Sale | Miller Steve | Chief Op. & Scientific Officer | 150,000 0.1243% | $20.35 | $3.05M | +3.82% | |
| 2024-08-09 | Sale | INGENITO GARY | Chief Med. & Reg. Officer | 100,000 0.0826% | $18.04 | $1.8M | +16.13% | |
| 2024-08-09 | Sale | Del Carmen Jeffrey | Chief Commercial Officer | 36,058 0.0304% | $18.42 | $664,310 | +16.13% | |
| 2024-06-07 | Sale | Del Carmen Jeffrey | Chief Commercial Officer | 7,541 0.0066% | $16.07 | $121,184 | +33.61% |
Total: 237
*Gray background shows transactions not older than one year
Insider Historical Profitability
42.07%
| MCENANY PATRICK J | Chairman of Board of Directors | 4478169 3.6873% | $94.94M | 36 | 14 | +56.08% |
| Miller Steve | Chief Op. & Scientific Officer | 686996 0.5657% | $14.56M | 3 | 9 | +36.11% |
| Tierney David S | director | 348874 0.2873% | $7.4M | 3 | 7 | +8.21% |
| BIOMARIN PHARMACEUTICAL INC | 10 percent owner | 6666667 5.4892% | $141.33M | 1 | 0 | +100% |
| HUCKEL HUBERT E MD | director | 1304134 1.0738% | $27.65M | 5 | 0 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$193,151,375 | 134 | 8.18% | $2.73B | |
Catalyst Pharmaceuticals, Inc. (CPRX) | $11,588,217 | 69 | 42.07% | $2.57B |
$1,376,668 | 53 | 18.46% | $2.29B | |
$140,165,669 | 33 | 85.24% | $3.25B | |
$1,275,975,557 | 32 | 19.44% | $2.8B |
CPRX Institutional Investors: Active Positions
| Increased Positions | 203 | +68.58% | 11M | +11.91% |
| Decreased Positions | 126 | -42.57% | 9M | -9.16% |
| New Positions | 61 | New | 3M | New |
| Sold Out Positions | 36 | Sold Out | 2M | Sold Out |
| Total Postitions | 373 | +26.01% | 98M | +2.75% |
CPRX Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $444,641.00 | 16.05% | 19.43M | +407,638 | +2.14% | 2024-12-31 |
| Vanguard Group Inc | $192,988.00 | 6.97% | 8.43M | +390,116 | +4.85% | 2024-12-31 |
| State Street Corp | $132,683.00 | 4.79% | 5.8M | +111,230 | +1.96% | 2024-12-31 |
| Deerfield Management Company, L.P. (Series C) | $71,715.00 | 2.59% | 3.13M | -3M | -49.71% | 2024-12-31 |
| Dimensional Fund Advisors Lp | $68,968.00 | 2.49% | 3.01M | -5,757 | -0.19% | 2024-12-31 |
| Pacer Advisors, Inc. | $67,652.00 | 2.44% | 2.96M | +151,495 | +5.4% | 2024-12-31 |
| Goldman Sachs Group Inc | $64,146.00 | 2.32% | 2.8M | +1M | +90.35% | 2024-12-31 |
| Renaissance Technologies Llc | $61,943.00 | 2.24% | 2.71M | +180,100 | +7.13% | 2024-12-31 |
| Geode Capital Management, Llc | $61,013.00 | 2.2% | 2.67M | +1,048 | +0.04% | 2024-12-31 |
| First Trust Advisors Lp | $51,132.00 | 1.85% | 2.23M | -195,139 | -8.03% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.